ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
14 hedge funds and large institutions have $36.5M invested in ESSA Pharma in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
90% more capital invested
Capital invested by funds: $19.2M → $36.5M (+$17.2M)
17% more funds holding
Funds holding: 12 → 14 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.87M |
| 2 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$6.92M |
| 3 |
AIC
AWM Investment Company
New York
|
+$3.16M |
| 4 |
DM
Deerfield Management
New York
|
+$2.37M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$84.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$36.1K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$23K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
EPIX Hedge Fund Activity: Q1 2016 in Review
14 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2016, worth a combined $36.5M — up 90% from $19.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EPIX positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $8.87M. The largest seller was DAFNA Capital Management, cutting an estimated $84.8K.
- 14 institutional investors held ESSA Pharma (EPIX) as of Q1 2016, up from 12 in Q4 2015.
- Funds reported $36.5M of ESSA Pharma stock for Q1 2016, up 90% quarter-over-quarter.
- 4 funds opened new ESSA Pharma positions in Q1 2016 and 2 closed out, a net change of +2 holders.
- The largest ESSA Pharma buyer in Q1 2016 was Eventide Asset Management, an estimated $8.87M added.
- The largest ESSA Pharma seller in Q1 2016 was DAFNA Capital Management, an estimated $84.8K sold.
Based on aggregated 13F filings for Q1 2016.